Skip to main content

Psychedelics & Neuroplastogens

Your Vanguard Partner for Psychedelic Drug Development

Ulysses Neuroscience provides a comprehensive translational platform for evaluating classical psychedelics and next-generation non-hallucinogenic neuroplastogens. With full regulatory authorisation to hold and test Schedule I compounds, HPRA- and AAALAC-accredited facilities, and over two decades of neuropharmacology expertise, we enable our partners to advance psychedelic research programmes with speed, regulatory compliance, and scientific rigour. Our integrated approach spans from in vivo efficacy in validated depression models to in vitro neuroplasticity mechanisms in both rodent primary neurons and human iPSC-derived systems—delivering the complete data package required for IND-enabling studies.

Classical Psychedelics

In vivo efficacy testing (psilocybin, DMT, 5-MeO-DMT, LSD, ketamine) in validated depression models with behavioural, biomarker, and EEG endpoints

Neuroplasticity Mechanisms

In vitro platforms featuring Sholl analysis, PSD-95 puncta quantification, BDNF secretion, and cytoskeletal plasticity markers in primary neurons and human iPSC-derived neurons

Non-Hallucinogenic Neuroplastogens

Head Twitch Response profiling for hallucinogenic potential, combined with neuroplasticity assays to characterise therapeutic mechanisms

Explore Our Full Therapeutic Expertise

Beyond neuropsychiatric disorders, Ulysses Neuroscience delivers comprehensive preclinical and translational services across the spectrum of CNS conditions. Our integrated platform—combining behavioural pharmacology, advanced biomarker technologies, EEG, and human iPSC-derived models—enables seamless translation from bench to bedside across multiple therapeutic areas.

Neuropsychiatric
Diseases

  • Depression & Treatment-Resistant Depression
  • Anxiety Disorders
  • Schizophrenia

Neurodegenerative Diseases

  • Alzheimer’s Disease
  • Parkinson’s Disease
  • Multiple Sclerosis
  • Amyotrophic Lateral Sclerosis (ALS)

Neuromuscular
Diseases

  • Charcot-Marie-Tooth Disease (CMT)

Neurodevelopmental Diseases

  • CDKL5 Deficiency Disorder (CDD)
  • Fragile X Syndrome (FXS)
  • Epilepsy & Seizure Disorders

Psychedelics and
Neuroplastogens

  • Classical psychedelics
  • Next-generation non-hallucinogenic neuroplastogens.